Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis
Information source: Fourth Military Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sepsis
Intervention: oxygen (Drug); Sevoflurane (Drug); Isoflurane (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Fourth Military Medical University Official(s) and/or principal investigator(s): Lichao Hou, M.D., Ph.D., Principal Investigator, Affiliation: Xijing Hospital, Fourth Military Medical University
Overall contact: Lichao Hou, M.D., Ph.D., Email: hou2001@fmmu.edu.cn
Summary
Sepsis is a major cause of death in intensive care units. Despite the investigators improved
understanding, which has reduced the risk of dying with sepsis, the number of people who die
each year continues to increase due to an overall increase in the number of cases. In our
previous study, the investigators have showed that 100% oxygen or 0. 5 minimum alveolar
concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line
against in-vitro sepsis induced by lipopolysaccharide (LPS).
In this study, the investigator hypothesized that treatment of 100% oxygen or 0. 5 MAC
isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis
induced by LPS or plasma from septic patients.
Clinical Details
Official title: In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Subcellular location of Nuclear Factor-KAPPA B p65 subunit
Secondary outcome: tumor necrosis factor-alphainterleukin- 1 beta interleukin 6
Detailed description:
100% oxygen or 0. 5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor
necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture
supernatant after stimulation of LPS or plasma from septic patients, and also inhibit the
nuclear location of nuclear factor-kappa B p65 subunit.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Human PBMCs were only isolated from the adult patients without sepsis/SIRS/infectious
diseases.
- The plasma for induction of clinical in-vitro sepsis, was only isolated from adult
patients with sepsis.
Exclusion Criteria:
- Patients who had been selected for other clinical trials in the 3 months before.
Locations and Contacts
Lichao Hou, M.D., Ph.D., Email: hou2001@fmmu.edu.cn
Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University,, Xi'an, Shaanxi 710032, China; Recruiting lichao Hou, Email: hou2001@fmmu.edu.cn
Additional Information
Starting date: June 2014
Last updated: July 6, 2014
|